Navigation Links
Actos Caused Bladder Cancer and Wrongful Death of New York Woman, Alleges Lawsuit Filed by Parker Waichman LLP
Date:7/9/2013

New York, New York (PRWEB) July 09, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Actos is to blame for the bladder cancer and subsequent wrongful death of a New York woman. The suit was filed on May 23, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1239). It is one of thousands of cases that have been filed as part of the multidistrict litigation (MDL) entitled In Re: Actos (pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants. Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation.

According to the Complaint, the Plaintiff’s Decedent started taking Actos in 2001. The Decedent was diagnosed with bladder cancer in December 2008 and subsequently died in June 2012, allegedly because of Actos’ side effects. The lawsuit alleges that the Decedent suffered from extensive pain and suffering and severe emotional distress as a result of using Actos. The drug also allegedly reduced the Decedent’s ability to enjoy life.

The U.S. Food and Drug Administration (FDA) has warned about the risks of taking Actos. In June 2011, the agency said that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk.

Some research studies support the notion of a link between Actos and bladder cancer. The British Medical Journal published a study on May 31, 2012, that revealed Actos users were twice as likely to develop bladder cancer after two years. Then, on July 3, 2012, the Canadian Medical Association Journal reported that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/actos-bladder-cancer/072013/prweb10912790.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Florida Man Develops Bladder Cancer as Result of Taking Actos, Alleges Lawsuit Filed by Parker Waichman LLP
2. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Recent Status Conference in Federal Actos Bladder Cancer Litigation
3. Actos Lawsuit News: Plaintiff Claims Actos Causes Bladder Cancer, Rottenstein Law Group LLP Reports
4. Lawsuit Alleging Actos Caused Arizona Man’s Bladder Cancer Filed by Parker Waichman LLP
5. Buckfire & Buckfire, P.C. Dangerous Drug Lawyers Now Accepting Michigan Actos Lawsuits
6. Actos Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Actos Bladder Cancer Litigation
7. Parker Waichman LLP Represents Pennsylvania Man in Lawsuit Alleging Actos Caused his Bladder Cancer
8. Actos Lawsuits: Bernstein Liebhard LLP Notes More Than 1,500 Cases Now Filed in Federal Litigation
9. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Actos Bladder Cancer Litigation
10. Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation
11. Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
(Date:5/27/2016)... PALMYRA, Wis. (PRWEB) , ... May 27, 2016 ... ... over $90,000 in scholarships to students studying complementary medicine. Allison Outerbridge is this ... She accepted her award on May 18 at the university’s Student Leadership Awards ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. ... been honored with a 2016 When Work Works Award for its use of effective ... the national When Work Works project administered by the Families and Work Institute (FWI) ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... , ... May 26, 2016 , ... There are nearly ... than 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the ... National Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... -- Niederländische Chirurgen haben eine innovative ... erlaubt, ihre Expertise weltweit zu teilen und so ... mit einer Instant-Messaging-Funktion und der Möglichkeit, in einem ... Afrika, Asien und den USA ... Information und Weiterbildung   "MDLinking ...
(Date:5/24/2016)... --   , Study met ... cleansing and superiority in , Excellent ... of the ascending colon   , ... Norgine B.V. today announced new positive data from the phase III ... versus standard 2 litre PEG with ascorbate. The study met both ...
Breaking Medicine Technology: